Mr. Soscia has 16 years of experience in the pharmaceutical industry, focusing on brand and generic finished dosage, as well as sourcing and development of bulk active pharmaceutical ingredients from the US, Europe and Asia. Mr. Soscia founded Medicor Actives, LLC, a company involved in the development and importation of generic bulk pharmaceutical ingredients from Asia.  Prior, he was the V.P. of Business Development for Bioprogress (UK:BPRG).  Additionally, Mr. Soscia has served in various sales and marketing positions with Roussel UCLAF (Subsidiary Sanofi Aventis) and Aceto Chemicals. Mr. Soscia holds an undergraduate degree in Biology with a concentration in Neurobiology, from Northwestern University studying under Dr. Steven Brem a pioneer in angiogenesis, and a Master’s of Science in Nutrition and Food Chemistry from the University of Arizona. Mr. Soscia is inventor or co-inventor of several of the Company's technologies.

Roland Gerritsen van der Hoop, M.D., Ph.D. - Chief Medical Officer / Scientific Officer

Dr. Gerritsen van der Hoop is Atlantic's Chief Medical and Scientific Officer. His expertise in drug development in general and analgesics in particular is pertinent in guiding Atlantic’s tamper resistant therapeutic platform clinical program. Dr. Gerritsen van der Hoop received his degrees in medicine and neuropharmacology at the University of Utrecht in the Netherlands. Between 1988 and 2002 he held a number of positions for Solvay in Weesp, the Netherlands and Marietta, GA, including those of Senior Vice-President of R&D and Chief Medical Officer. From 2003 to 2007 he served as Senior Vice-President for Research, Development and Regulatory Affairs at Endo Pharmaceuticals, during which time Endo obtained market authorization for two new opioid therapeutics, Opana® and Opana ER®. Prior to joining Endo, Dr. Gerritsen van der Hoop was Vice-President of Global Research and Development and Chief Scientific Officer at Serologicals Corporation. He most recently also served as Chief Scientific Officer of Celtaxsys in Atlanta GA. and as consultant to a number of pharmaceutical companies.

Dr. Johnson is an established and recognized expert in the pharmaceutical sciences, and specifically, drug delivery technologies.  Dr. Johnson has over 40 years of experience in the pharmaceutical industry and is an expert in semi-solids and solids formulation.  Over the last 20 years, he has been Vice-President of three different pharmaceutical divisions of Schering Plough, including Pharmaceutical/Suncare Division, the Pharmaceutical/Toiletries Division, and the Proprietary Drug and Toiletry Division. While at Schering Plough, he was responsible for the development of several skin care products, including Coppertone Sport, Coppertone Water Babies, Coppertone Kids, and other unique and international sun and skin care products.  Prior to his tenure at Schering Plough, he was the Section Head of Pharmaceutical Development for Ayerst Laboratories.  Additionally, Dr. Johnson is the Co-Founder and Co-Director of the "Hands on Course in Tablet Technology at the University of Tennessee and has published several articles relating to pellet technology, injectable drug delivery systems, biodegradable drug delivery systems, and other related technologies.  Over the last five years he has supported research projects dealing with controlled release naltrexone, controlled release ceftiofur, and various oral solid dosage forms of various drugs.  Dr. Johnson earned his Ph.D. in Pharmaceutics from the University of Minnesota.  He also earned a Master's Degree in Pharmaceutics and a Bachelor's Degree in Pharmacy from the University of Wisconsin. Dr. Johnson is inventor or co-inventor of several of the Company's technologies.

Dr. Shukla is an expert in drug delivery systems and a Professor in the Department of Pharmaceutical Sciences at the University of Tennessee, Memphis.  Dr. Shukla owns several U.S. patents related to drug delivery technology.  In addition to his patented work, Dr. Shukla has numerous publications and several pending patent applications dealing with topics ranging from oral tablet technologies, controlled release pharmaceuticals, polymer based drug delivery systems, and injectable drug delivery systems.  He has published chapters in four books, including the High Shear Granulation in Handbook of Pharmaceutical Granulation Technology, Dissolution of Solid Oral dosage forms in Dissolution Theory, Methodology and Testing, and two chapters in the Handbook of Pharmaceutical Excipients. Dr. Shukla earned his Ph.D. in Pharmaceutics from the University of Georgia, Athens in 1985.  He also earned his Master's Degree in Pharmaceutics from the University of Georgia.  He earned his Bachelor's Degree in Pharmacy from University of Bombay, Bombay, India.  He has provided research support to foreign and domestic pharmaceutical companies, and has also provided research support to a project funded by the U.S. Food and Drug Administration. Dr. Shukla is inventor or co-inventor of several of the Company's technologies.

Dr. Vashi is a regulatory and clinical expert in analgesic therapeutics.  Currently, he is the Vice President of Clinical Pharmacology for MDS Pharma Services.  Dr. Vashi has extensive experience in the pharmaceutical industry and in navigating the regulatory requirements of the FDA.  He has worked on all stages of pharmaceutical research and development, from Discover to Early Clinical Research and through Phases I, IIa, III, and IV of clinical trials.  He has conducted “First in Human” studies for new drug candidates in several therapeutic areas, including oncology, obesity, and inflammation.  He has also provided clinical input into and interpretation of PK/PD and population data from Phase II and Phase III programs and has prepared PK/PD study reports and PK/Biopharmaceutics summaries for NDA and MAAs. Prior to joining MDS, Dr. Vashi helped to develop OxyContin™ at Purdue Pharma, where he was the Senior Director of Clinical Pharmaceuticals.  Dr. Vashi was also a Director of Clinical Pharmacology for 9 years at Pfizer, Inc.  Dr. Vashi earned both his Ph.D. and Master’s Degree in Pharmacokinetics/ Biopharmaceutics from the University of Tennessee.  He has been published in over ten peer reviewed publications and has been invited to present his research and data for close to twenty events, including the American Pain Society, the American Academy of Pain Medicine.

Dr. Laizure is currently a clinical Pharmacist at the VAMC Psychiatry Services, Memphis,  and holds a joint appointment as Associate Professor of Clinical Pharmacy at the University of Tennessee. Dr. Laizure's expertise in addiction treatment has been instumental in directing Atlantic's clinical and research programs leading to NIH funding. Dr. Laizure has served as Fellow in Clinical Pharmacokinetics with Dr. D. Robinson, U. of Florida and as Research Associate, Dept. Pharmacy Practice, University of Florida. Dr. Laizure has authored numerous publications related to alcohol and narcotic addition therapies and has been a pricipal investigator on NIH studies with nalmefene implantable controlled-release pellets.

Dr. Mandrel has been instumental in the Atlantic’s pursuit of sustained release depots for analgesia in research animals. Dr. Mandrell is currently Professor and Chair, Department of Comparative Medicine, University of Tennessee Health Science Center and Chief, Veterinary Medical Unit, VA Medical Center, Memphis, Tennessee. He has been instumental in directing Atlantic's NIH program related to analgesia in animals. Dr. Mandrell has also served as acting chair and assistant professor as well as Staff Veterinarian in the Department of Comparative Medicine, University of Tennessee. Prior, Dr. Mandrel was Senior Staff Veterinarian for Laboratory Animals and Research Facilities, U.S. Department of Agriculture, Animal and Plant Health Inspection Service, Animal Care Staff, Hyattsville, Maryland and Clinical Veterinarian, Office of Laboratory Animal Science, National Cancer Institute, NIH. Dr. Mandrell was a Postdoctoral Fellow in Laboratory Animal Medicine, Division of Comparative Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Dr. Mandrel’s research interests include comparative medicine analysis between research animals and human pharmacodynamic systems. He has published numerous papers in the field of illicit drug and alcohol interations with animal models.